Monoclonal antibodies protect aged rhesus macaques from SARS-CoV-2-induced immune activation and neuroinflammation

Anti-viral monoclonal antibody (mAb) treatments may provide immediate but short-term immunity from coronavirus disease 2019 (COVID-19) in high-risk populations, such as people with diabetes and the elderly; however, data on their efficacy in these populations are limited. We demonstrate that prophyl...

Descripción completa

Detalles Bibliográficos
Autores principales: Verma, Anil, Hawes, Chase E., Lakshmanappa, Yashavanth Shaan, Roh, Jamin W., Schmidt, Brian A., Dutra, Joseph, Louie, William, Liu, Hongwei, Ma, Zhong-Min, Watanabe, Jennifer K., Usachenko, Jodie L., Immareddy, Ramya, Sammak, Rebecca L., Pollard, Rachel, Reader, J. Rachel, Olstad, Katherine J., Coffey, Lark L., Kozlowski, Pamela A., Hartigan-O’Connor, Dennis J., Nussenzweig, Michel, Van Rompay, Koen K.A., Morrison, John H., Iyer, Smita S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cell Press 2021
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8523485/
https://www.ncbi.nlm.nih.gov/pubmed/34706272
http://dx.doi.org/10.1016/j.celrep.2021.109942

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8523485/
https://www.ncbi.nlm.nih.gov/pubmed/34706272
http://dx.doi.org/10.1016/j.celrep.2021.109942

Ejemplares similares